20.69
price up icon4.76%   0.94
after-market 시간 외 거래: 20.61 -0.08 -0.39%
loading
전일 마감가:
$19.75
열려 있는:
$19.91
하루 거래량:
1.54M
Relative Volume:
0.64
시가총액:
$15.26B
수익:
$956.00K
순이익/손실:
$-196.68M
주가수익비율:
-86.21
EPS:
-0.24
순현금흐름:
$-113.02M
1주 성능:
+2.78%
1개월 성능:
+9.82%
6개월 성능:
-13.79%
1년 성능:
+513.95%
1일 변동 폭
Value
$19.63
$20.82
1주일 범위
Value
$19.13
$20.82
52주 변동 폭
Value
$2.10
$33.89

Summit Therapeutics Inc Stock (SMMT) Company Profile

Name
명칭
Summit Therapeutics Inc
Name
전화
305-203-2034
Name
주소
601 BRICKELL KEY DRIVE, MIAMI
Name
직원
159
Name
트위터
@summitplc
Name
다음 수익 날짜
2025-02-24
Name
최신 SEC 제출 서류
Name
SMMT's Discussions on Twitter

SMMT을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
SMMT
Summit Therapeutics Inc
20.69 15.26B 956.00K -196.68M -113.02M -0.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
511.74 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
661.00 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
290.70 37.63B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ARGX
Argen X Se Adr
607.95 37.08B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ONC
Beigene Ltd Adr
253.20 27.23B 3.81B -644.79M -669.77M -6.24

Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-03-21 개시 Cantor Fitzgerald Overweight
2025-03-12 개시 Evercore ISI Outperform
2025-02-28 개시 Goldman Buy
2025-01-08 개시 Truist Buy
2024-12-11 개시 Wells Fargo Overweight
2024-12-06 개시 Jefferies Buy
2024-11-04 개시 JMP Securities Mkt Outperform
2024-09-27 다운그레이드 Citigroup Buy → Neutral
2024-08-12 개시 H.C. Wainwright Buy
2024-05-07 개시 Citigroup Buy
2024-03-26 개시 Stifel Buy
2018-06-28 다운그레이드 Janney Buy → Neutral
2018-05-02 개시 Janney Buy
2018-04-12 재확인 Needham Buy
2018-02-13 개시 BTIG Research Buy
2018-01-04 개시 SunTrust Buy
2017-12-01 재개 H.C. Wainwright Buy
2016-11-16 재확인 RBC Capital Mkts Outperform
2016-10-05 재확인 Needham Buy
2016-09-16 개시 H.C. Wainwright Buy
2015-03-30 개시 Needham Buy
2015-03-30 개시 Oppenheimer Outperform
모두보기

Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스

pulisher
02:17 AM

Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics - Benzinga

02:17 AM
pulisher
12:45 PM

Summit CEO Bob Duggan Sued Over 'Outlandish' Self-Dealing Loan - Bloomberg Law

12:45 PM
pulisher
Mar 23, 2025

Is Summit Therapeutics a Millionaire Maker? - Nasdaq

Mar 23, 2025
pulisher
Mar 22, 2025

Cantor Fitzgerald Initiates Coverage of Summit Therapeutics (BMV:SMMT) with Overweight Recommendation - Nasdaq

Mar 22, 2025
pulisher
Mar 22, 2025

Summit rises as Cantor becomes latest to launch with a bullish view - MSN

Mar 22, 2025
pulisher
Mar 21, 2025

Cantor Fitzgerald Initiates Coverage of Summit Therapeutics (SMMT) with Overweight Recommendation - Nasdaq

Mar 21, 2025
pulisher
Mar 21, 2025

Summit Therapeutics grants stock options to new employees By Investing.com - Investing.com Canada

Mar 21, 2025
pulisher
Mar 21, 2025

Summit Therapeutics grants stock options to new employees - Investing.com India

Mar 21, 2025
pulisher
Mar 21, 2025

Summit Therapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4) -March 21, 2025 at 04:20 pm EDT - Marketscreener.com

Mar 21, 2025
pulisher
Mar 21, 2025

Summit Therapeutics Awards 147,500 Shares in Strategic Employee Stock Options - StockTitan

Mar 21, 2025
pulisher
Mar 21, 2025

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance UK

Mar 21, 2025
pulisher
Mar 21, 2025

Summit stock rises after Cantor's bullish view (SMMT:NASDAQ) - Seeking Alpha

Mar 21, 2025
pulisher
Mar 21, 2025

Cantor Fitzgerald Initiates Summit Therapeutics at Overweight -March 21, 2025 at 07:27 am EDT - Marketscreener.com

Mar 21, 2025
pulisher
Mar 19, 2025

This Unstoppable Biotech Stock Just Became an Even Better Buy - The Globe and Mail

Mar 19, 2025
pulisher
Mar 18, 2025

Summit Therapeutics Names Robert LaCaze as Chief Commercial Officer -March 18, 2025 at 03:30 am EDT - Marketscreener.com

Mar 18, 2025
pulisher
Mar 17, 2025

Summit Therapeutics : Completion of $50 million Fundraising and Directorate Change - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Billion-Dollar Oncology Expert Robert LaCaze to Drive Summit Therapeutics Cancer Drug Launch - StockTitan

Mar 17, 2025
pulisher
Mar 17, 2025

Evercore ISI Group Initiates Coverage of Summit Therapeutics (BMV:SMMT) with Outperform Recommendation - Nasdaq

Mar 17, 2025
pulisher
Mar 16, 2025

Summit gains as Evercore highlights potential to rival Merck’s Keytruda - MSN

Mar 16, 2025
pulisher
Mar 16, 2025

Applovin, Super Micro Computer And Intel Among Top 10 Large-Cap Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio? - Benzinga

Mar 16, 2025
pulisher
Mar 16, 2025

Summit Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:SMMT - Benzinga

Mar 16, 2025
pulisher
Mar 14, 2025

(SMMT) On The My Stocks Page - Stock Traders Daily

Mar 14, 2025
pulisher
Mar 14, 2025

Summit Therapeutics issues stock options to new employees By Investing.com - Investing.com Australia

Mar 14, 2025
pulisher
Mar 14, 2025

Summit Therapeutics issues stock options to new employees - Investing.com India

Mar 14, 2025
pulisher
Mar 14, 2025

Summit Therapeutics Awards 122,650 Shares in Employee Stock Options at $18.50 - StockTitan

Mar 14, 2025
pulisher
Mar 14, 2025

Summit Therapeutics Stock Climbs 4%, Share Price Hits $19.96 - TradingPedia

Mar 14, 2025
pulisher
Mar 14, 2025

Why Summit Therapeutics Stock Was Winning This Week - MSN

Mar 14, 2025
pulisher
Mar 14, 2025

SMMT Gains on Bullish Analyst Coverage - GuruFocus.com

Mar 14, 2025
pulisher
Mar 14, 2025

Summit Therapeutics (NASDAQ:SMMT) Coverage Initiated at Evercore ISI - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Is Summit Therapeutics Inc. (SMMT) the Best Multibagger Stock to Buy in 2025? - Insider Monkey

Mar 13, 2025
pulisher
Mar 13, 2025

This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Year - Nasdaq

Mar 13, 2025
pulisher
Mar 12, 2025

Evercore ISI Initiates Summit Therapeutics at Outperform With $30 Price Target -March 12, 2025 at 12:08 pm EDT - Marketscreener.com

Mar 12, 2025
pulisher
Mar 12, 2025

Summit Therapeutics Shares Surge on Promising Trial Results - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

Evercore ISI Group Initiates Coverage of Summit Therapeutics (SMMT) with Outperform Recommendation - Nasdaq

Mar 12, 2025
pulisher
Mar 12, 2025

Summit Therapeutics initiated with an Outperform at Evercore ISI - TipRanks

Mar 12, 2025
pulisher
Mar 11, 2025

12 Best Multibagger Stocks to Buy in 2025 - Insider Monkey

Mar 11, 2025
pulisher
Mar 11, 2025

Stifel maintains Buy on Summit Therapeutics, $40 target By Investing.com - Investing.com Canada

Mar 11, 2025
pulisher
Mar 08, 2025

Summit Therapeutics Inc. (SMMT): Why Are Analysts Bullish On This Hot Growth Stock Right Now? - Insider Monkey

Mar 08, 2025
pulisher
Mar 05, 2025

New York State Common Retirement Fund Grows Stake in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World

Mar 05, 2025
pulisher
Mar 05, 2025

Principal Financial Group Inc. Acquires 147,003 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World

Mar 05, 2025
pulisher
Mar 05, 2025

Summit Therapeutics (NASDAQ:SMMT) Stock Rating Upgraded by StockNews.com - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

(SMMT) Investment Analysis and Advice - Stock Traders Daily

Mar 04, 2025
pulisher
Mar 04, 2025

Rhumbline Advisers Has $2.23 Million Stock Position in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World

Mar 04, 2025
pulisher
Mar 01, 2025

Summit Therapeutics (NASDAQ:SMMT) Earns Buy Rating from Analysts at The Goldman Sachs Group - MarketBeat

Mar 01, 2025
pulisher
Mar 01, 2025

Equities Analysts Offer Predictions for SMMT Q1 Earnings - MarketBeat

Mar 01, 2025
pulisher
Mar 01, 2025

Summit Therapeutics' (SMMT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

Mar 01, 2025
pulisher
Mar 01, 2025

Goldman Sachs Initiates Coverage of Summit Therapeutics (SMMT) with Buy Recommendation - MSN

Mar 01, 2025
pulisher
Feb 28, 2025

StockNews.com Downgrades Summit Therapeutics (NASDAQ:SMMT) to Sell - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga

Feb 28, 2025
pulisher
Feb 28, 2025

Summit Therapeutics Stock Surges Amid Promising Trials - TipRanks

Feb 28, 2025

Summit Therapeutics Inc (SMMT) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$33.75
price up icon 0.15%
$79.38
price down icon 0.68%
$319.86
price up icon 2.19%
$100.64
price up icon 5.51%
biotechnology ONC
$253.20
price up icon 0.48%
자본화:     |  볼륨(24시간):